CONMED CORP (CNMD) Fundamental Analysis & Valuation

NYSE:CNMD • US2074101013

Current stock price

35.245 USD
-1.4 (-3.81%)
Last:

This CNMD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. CNMD Profitability Analysis

1.1 Basic Checks

  • In the past year CNMD was profitable.
  • In the past year CNMD had a positive cash flow from operations.
  • Of the past 5 years CNMD 4 years were profitable.
  • Each year in the past 5 years CNMD had a positive operating cash flow.
CNMD Yearly Net Income VS EBIT VS OCF VS FCFCNMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M 200M

1.2 Ratios

  • CNMD has a better Return On Assets (2.02%) than 74.07% of its industry peers.
  • CNMD has a better Return On Equity (4.55%) than 76.19% of its industry peers.
  • CNMD has a Return On Invested Capital of 4.23%. This is in the better half of the industry: CNMD outperforms 73.55% of its industry peers.
  • CNMD had an Average Return On Invested Capital over the past 3 years of 5.32%. This is below the industry average of 9.31%.
Industry RankSector Rank
ROA 2.02%
ROE 4.55%
ROIC 4.23%
ROA(3y)3.52%
ROA(5y)2.12%
ROE(3y)8.68%
ROE(5y)4.64%
ROIC(3y)5.32%
ROIC(5y)4.74%
CNMD Yearly ROA, ROE, ROICCNMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 -5 10 -10

1.3 Margins

  • CNMD's Profit Margin of 3.42% is fine compared to the rest of the industry. CNMD outperforms 75.13% of its industry peers.
  • CNMD's Profit Margin has improved in the last couple of years.
  • Looking at the Operating Margin, with a value of 8.39%, CNMD is in the better half of the industry, outperforming 75.66% of the companies in the same industry.
  • CNMD's Operating Margin has improved in the last couple of years.
  • CNMD has a Gross Margin (54.59%) which is in line with its industry peers.
  • In the last couple of years the Gross Margin of CNMD has remained more or less at the same level.
Industry RankSector Rank
OM 8.39%
PM (TTM) 3.42%
GM 54.59%
OM growth 3Y4.64%
OM growth 5Y1.5%
PM growth 3YN/A
PM growth 5Y25.45%
GM growth 3Y-0.47%
GM growth 5Y-0.15%
CNMD Yearly Profit, Operating, Gross MarginsCNMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40

4

2. CNMD Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CNMD is destroying value.
  • Compared to 1 year ago, CNMD has more shares outstanding
  • CNMD has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, CNMD has an improved debt to assets ratio.
CNMD Yearly Shares OutstandingCNMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
CNMD Yearly Total Debt VS Total AssetsCNMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • CNMD has an Altman-Z score of 1.82. This is not the best score and indicates that CNMD is in the grey zone with still only limited risk for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 1.82, CNMD is in line with its industry, outperforming 58.20% of the companies in the same industry.
  • CNMD has a debt to FCF ratio of 5.53. This is a neutral value as CNMD would need 5.53 years to pay back of all of its debts.
  • CNMD's Debt to FCF ratio of 5.53 is fine compared to the rest of the industry. CNMD outperforms 77.25% of its industry peers.
  • CNMD has a Debt/Equity ratio of 0.81. This is a neutral value indicating CNMD is somewhat dependend on debt financing.
  • CNMD has a worse Debt to Equity ratio (0.81) than 70.37% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.81
Debt/FCF 5.53
Altman-Z 1.82
ROIC/WACC0.47
WACC8.92%
CNMD Yearly LT Debt VS Equity VS FCFCNMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.3 Liquidity

  • A Current Ratio of 2.14 indicates that CNMD has no problem at all paying its short term obligations.
  • The Current ratio of CNMD (2.14) is comparable to the rest of the industry.
  • A Quick Ratio of 1.01 indicates that CNMD should not have too much problems paying its short term obligations.
  • CNMD has a Quick ratio of 1.01. This is in the lower half of the industry: CNMD underperforms 77.78% of its industry peers.
Industry RankSector Rank
Current Ratio 2.14
Quick Ratio 1.01
CNMD Yearly Current Assets VS Current LiabilitesCNMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

4

3. CNMD Growth Analysis

3.1 Past

  • CNMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.82%, which is quite good.
  • CNMD shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 16.37% yearly.
  • The Revenue has been growing slightly by 5.18% in the past year.
  • The Revenue has been growing by 9.77% on average over the past years. This is quite good.
EPS 1Y (TTM)10.82%
EPS 3Y20.27%
EPS 5Y16.37%
EPS Q2Q%6.72%
Revenue 1Y (TTM)5.18%
Revenue growth 3Y9.55%
Revenue growth 5Y9.77%
Sales Q2Q%7.88%

3.2 Future

  • The Earnings Per Share is expected to grow by 7.09% on average over the next years.
  • CNMD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.55% yearly.
EPS Next Y-3.63%
EPS Next 2Y4.41%
EPS Next 3Y7.09%
EPS Next 5YN/A
Revenue Next Year-0.72%
Revenue Next 2Y2.34%
Revenue Next 3Y3.55%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CNMD Yearly Revenue VS EstimatesCNMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 500M 1B 1.5B
CNMD Yearly EPS VS EstimatesCNMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1 2 3 4 5

8

4. CNMD Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 7.65, the valuation of CNMD can be described as very cheap.
  • CNMD's Price/Earnings ratio is rather cheap when compared to the industry. CNMD is cheaper than 94.71% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 25.23. CNMD is valued rather cheaply when compared to this.
  • The Price/Forward Earnings ratio is 7.93, which indicates a rather cheap valuation of CNMD.
  • Based on the Price/Forward Earnings ratio, CNMD is valued cheaply inside the industry as 96.83% of the companies are valued more expensively.
  • CNMD's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.51.
Industry RankSector Rank
PE 7.65
Fwd PE 7.93
CNMD Price Earnings VS Forward Price EarningsCNMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • CNMD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. CNMD is cheaper than 91.53% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of CNMD indicates a rather cheap valuation: CNMD is cheaper than 99.47% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 7.2
EV/EBITDA 10.15
CNMD Per share dataCNMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 30 40

4.3 Compensation for Growth

  • CNMD has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.47
EPS Next 2Y4.41%
EPS Next 3Y7.09%

7

5. CNMD Dividend Analysis

5.1 Amount

  • CNMD has a Yearly Dividend Yield of 2.17%. Purely for dividend investing, there may be better candidates out there.
  • CNMD's Dividend Yield is rather good when compared to the industry average which is at 0.24. CNMD pays more dividend than 95.77% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.90, CNMD has a dividend comparable with the average S&P500 company.
Industry RankSector Rank
Dividend Yield 2.17%

5.2 History

  • The dividend of CNMD has a limited annual growth rate of 0.10%.
  • CNMD has paid a dividend for at least 10 years, which is a reliable track record.
  • CNMD has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)0.1%
Div Incr Years0
Div Non Decr Years12
CNMD Yearly Dividends per shareCNMD Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6

5.3 Sustainability

  • 52.59% of the earnings are spent on dividend by CNMD. This is a bit on the high side, but may be sustainable.
  • CNMD's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP52.59%
EPS Next 2Y4.41%
EPS Next 3Y7.09%
CNMD Yearly Income VS Free CF VS DividendCNMD Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M
CNMD Dividend Payout.CNMD Dividend Payout, showing the Payout Ratio.CNMD Dividend Payout.PayoutRetained Earnings

CNMD Fundamentals: All Metrics, Ratios and Statistics

CONMED CORP

NYSE:CNMD (3/27/2026, 2:53:09 PM)

35.245

-1.4 (-3.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)01-28
Earnings (Next)04-28
Inst Owners112.69%
Inst Owner Change-5.24%
Ins Owners0.28%
Ins Owner Change0.83%
Market Cap1.09B
Revenue(TTM)1.37B
Net Income(TTM)47.05M
Analysts73.33
Price Target48.35 (37.18%)
Short Float %7.95%
Short Ratio4.2
Dividend
Industry RankSector Rank
Dividend Yield 2.17%
Yearly Dividend0.8
Dividend Growth(5Y)0.1%
DP52.59%
Div Incr Years0
Div Non Decr Years12
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.3%
Min EPS beat(2)0.66%
Max EPS beat(2)5.94%
EPS beat(4)4
Avg EPS beat(4)5.44%
Min EPS beat(4)0.37%
Max EPS beat(4)14.78%
EPS beat(8)8
Avg EPS beat(8)5.62%
EPS beat(12)11
Avg EPS beat(12)4.63%
EPS beat(16)13
Avg EPS beat(16)0.77%
Revenue beat(2)0
Avg Revenue beat(2)-0.64%
Min Revenue beat(2)-1.03%
Max Revenue beat(2)-0.25%
Revenue beat(4)1
Avg Revenue beat(4)-0.38%
Min Revenue beat(4)-1.03%
Max Revenue beat(4)0.51%
Revenue beat(8)1
Avg Revenue beat(8)-0.84%
Revenue beat(12)3
Avg Revenue beat(12)-0.05%
Revenue beat(16)4
Avg Revenue beat(16)-1.46%
PT rev (1m)-2.47%
PT rev (3m)-2.07%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-12.72%
EPS NY rev (1m)-1.9%
EPS NY rev (3m)-2.43%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.91%
Revenue NY rev (1m)-1%
Revenue NY rev (3m)-1.35%
Valuation
Industry RankSector Rank
PE 7.65
Fwd PE 7.93
P/S 0.79
P/FCF 7.2
P/OCF 6.37
P/B 1.05
P/tB N/A
EV/EBITDA 10.15
EPS(TTM)4.61
EY13.08%
EPS(NY)4.44
Fwd EY12.61%
FCF(TTM)4.89
FCFY13.89%
OCF(TTM)5.54
OCFY15.71%
SpS44.59
BVpS33.51
TBVpS-11.55
PEG (NY)N/A
PEG (5Y)0.47
Graham Number58.96
Profitability
Industry RankSector Rank
ROA 2.02%
ROE 4.55%
ROCE 5.74%
ROIC 4.23%
ROICexc 4.31%
ROICexgc 14.63%
OM 8.39%
PM (TTM) 3.42%
GM 54.59%
FCFM 10.98%
ROA(3y)3.52%
ROA(5y)2.12%
ROE(3y)8.68%
ROE(5y)4.64%
ROIC(3y)5.32%
ROIC(5y)4.74%
ROICexc(3y)5.4%
ROICexc(5y)4.81%
ROICexgc(3y)19.18%
ROICexgc(5y)17.21%
ROCE(3y)7.22%
ROCE(5y)6.44%
ROICexgc growth 3Y7.2%
ROICexgc growth 5Y4.14%
ROICexc growth 3Y14.69%
ROICexc growth 5Y5.99%
OM growth 3Y4.64%
OM growth 5Y1.5%
PM growth 3YN/A
PM growth 5Y25.45%
GM growth 3Y-0.47%
GM growth 5Y-0.15%
F-Score5
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0.81
Debt/FCF 5.53
Debt/EBITDA 4.4
Cap/Depr 26.66%
Cap/Sales 1.44%
Interest Coverage 4.54
Cash Conversion 90.02%
Profit Quality 320.65%
Current Ratio 2.14
Quick Ratio 1.01
Altman-Z 1.82
F-Score5
WACC8.92%
ROIC/WACC0.47
Cap/Depr(3y)23.78%
Cap/Depr(5y)24.75%
Cap/Sales(3y)1.32%
Cap/Sales(5y)1.51%
Profit Quality(3y)200.6%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10.82%
EPS 3Y20.27%
EPS 5Y16.37%
EPS Q2Q%6.72%
EPS Next Y-3.63%
EPS Next 2Y4.41%
EPS Next 3Y7.09%
EPS Next 5YN/A
Revenue 1Y (TTM)5.18%
Revenue growth 3Y9.55%
Revenue growth 5Y9.77%
Sales Q2Q%7.88%
Revenue Next Year-0.72%
Revenue Next 2Y2.34%
Revenue Next 3Y3.55%
Revenue Next 5YN/A
EBIT growth 1Y-44.98%
EBIT growth 3Y14.64%
EBIT growth 5Y11.42%
EBIT Next Year26.75%
EBIT Next 3Y14.3%
EBIT Next 5YN/A
FCF growth 1Y-1.95%
FCF growth 3Y135.18%
FCF growth 5Y23.98%
OCF growth 1Y2.23%
OCF growth 3Y72.25%
OCF growth 5Y21.49%

CONMED CORP / CNMD Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CONMED CORP (CNMD) stock?

ChartMill assigns a fundamental rating of 5 / 10 to CNMD.


Can you provide the valuation status for CONMED CORP?

ChartMill assigns a valuation rating of 8 / 10 to CONMED CORP (CNMD). This can be considered as Undervalued.


How profitable is CONMED CORP (CNMD) stock?

CONMED CORP (CNMD) has a profitability rating of 6 / 10.


Can you provide the PE and PB ratios for CNMD stock?

The Price/Earnings (PE) ratio for CONMED CORP (CNMD) is 7.65 and the Price/Book (PB) ratio is 1.05.


What is the expected EPS growth for CONMED CORP (CNMD) stock?

The Earnings per Share (EPS) of CONMED CORP (CNMD) is expected to decline by -3.63% in the next year.